Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL PHARMA SAVOIE INVEST : revenue, balance sheet and financial ratios

SPFPL PHARMA SAVOIE INVEST is a French company founded 10 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in CHALLES-LES-EAUX (73190), this company of category PME shows in 2018 a revenue of 2.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL PHARMA SAVOIE INVEST (SIREN 818046039)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C N/C 2 099 038 € N/C
Net income 166 549 € 100 111 € 111 271 € 167 686 € 114 473 € 127 310 € 121 328 € 123 048 € 67 883 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 189 910 € N/C
Net margin N/C N/C N/C N/C N/C N/C N/C 5.9% N/C

Revenue and income statement

In 2025, SPFPL PHARMA SAVOIE INVEST generates positive net income of 167 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 68 k€ -> 167 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

166 549 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 33%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

33.054%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

63.652%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

46.0%

Solvency indicators evolution
SPFPL PHARMA SAVOIE INVEST

Sector positioning

Debt ratio
33.05 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average -13 pts over 3 years

In 2025, the debt ratio of SPFPL PHARMA SAVOIE INVEST (33.05) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
63.65% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good +12 pts over 3 years

In 2025, the financial autonomy of SPFPL PHARMA SAVOIE INVEST (63.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 154.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

154.151

Liquidity indicators evolution
SPFPL PHARMA SAVOIE INVEST

Sector positioning

Liquidity ratio
154.15 2025
2023
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Watch

In 2025, the liquidity ratio of SPFPL PHARMA SAVOIE INVEST (154.15) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SPFPL PHARMA SAVOIE INVEST

Positioning of SPFPL PHARMA SAVOIE INVEST in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of SPFPL PHARMA SAVOIE INVEST is estimated at 1 726 580 € (range 1 070 228€ - 2 685 376€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
1070k€ 1726k€ 2685k€
1 726 580 € Range: 1 070 228€ - 2 685 376€
NAF 5 all-time

Valuation method used

Net Income Multiple
166 549 € × 10.4x = 1 726 580 €
Range: 1 070 229€ - 2 685 376€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL PHARMA SAVOIE INVEST with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL PHARMA SAVOIE INVEST

What is the revenue of SPFPL PHARMA SAVOIE INVEST ?

The revenue of SPFPL PHARMA SAVOIE INVEST in 2018 is 2.1 M€.

Is SPFPL PHARMA SAVOIE INVEST profitable?

Yes, SPFPL PHARMA SAVOIE INVEST generated a net profit of 167 k€ in 2025.

Where is the headquarters of SPFPL PHARMA SAVOIE INVEST ?

The headquarters of SPFPL PHARMA SAVOIE INVEST is located in CHALLES-LES-EAUX (73190), in the department Savoie.

Where to find the tax return of SPFPL PHARMA SAVOIE INVEST ?

The tax return of SPFPL PHARMA SAVOIE INVEST is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL PHARMA SAVOIE INVEST operate?

SPFPL PHARMA SAVOIE INVEST operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.